Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder

(2014) Yuan-Hong Jiang et al.   PLoS One

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

(2013) Christopher Chapple et al.   EUROPEAN UROLOGY

OnabotulinumtoxinA Office Treatment for Neurogenic Bladder Incontinence in Parkinson's Disease

(2013) Rodney U. Anderson et al.   UROLOGY

Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)

(2012) Amar Mohee et al.   BJU INTERNATIONAL

OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial

(2012) Clare J. Fowler et al.   EUROPEAN UROLOGY

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity

(2012) Chun-Hou Liao et al.   JOURNAL OF UROLOGY

Repeated Botulinum Toxin Type A Injections for Refractory Overactive Bladder: Medium-Term Outcomes, Safety Profile, and Discontinuation Rates

(2011) Christopher Dowson et al.   EUROPEAN UROLOGY

Botulinum Toxin Type A in Patients With Parkinson's Disease and Refractory Overactive Bladder

(2011) Antonella Giannantoni et al.   JOURNAL OF UROLOGY

Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxina injection for idiopathic detrusor overactivity

(2011) Hann-Chorng Kuo   NEUROUROLOGY AND URODYNAMICS

Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms: A Longitudinal Population-Based Survey in Men Aged 45–103 Years

(2010) Ulf G.H. Malmsten et al.   EUROPEAN UROLOGY

Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome

(2010) Hann-Chorng Kuo et al.   EUROPEAN UROLOGY

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

(2010) Roger Dmochowski et al.   JOURNAL OF UROLOGY

An international urogynecological association (IUGA)/international continence society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic flo

(2010) Bernard T. Haylen et al.   NEUROUROLOGY AND URODYNAMICS

Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease

(2010) Haluk Kulaksizoglu et al.   PARKINSONISM & RELATED DISORDERS

Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report

(2008) Apostolos Apostolidis et al.   EUROPEAN UROLOGY

Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection

(2008) Linda Brubaker et al.   JOURNAL OF UROLOGY